Effect of Probiotics on Helicobacter Pylori Eradication
Effect of Probiotics on Helicobacter Pylori Eradication
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium
 quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse
 reactions of Helicobacter pylori quadruple eradication therapy and its influence on
 gastrointestinal flora.
Bismuth agent quadruple therapy (including bismuth agent and proton pump inhibitor combined
 with two antibiotics) is the first-line strategy to eradicate Helicobacter pylori in China.
 However, it may cause a series of adverse reactions, such as nausea, diarrhea, abdominal
 pain, constipation, and abnormal taste, etc., which leads to a decrease in patient
 compliance, thereby affecting the treatment effect. Many studies have found that adding
 probiotics to traditional Helicobacter pylori eradication therapies increase eradication
 rates and reduce the side effects of the treatment. Bifidobacterium tetrad live bacteria
 tablet is a compound microecological preparation composed of bifidobacterium infantis,
 lactobacillus acidophilus, enterococcus faecalis and bacillus cereus. This study aims to
 observe the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian
 Kang) on reducing the incidence rate of adverse reactions in Helicobacter pylori quadruple
 eradication therapy and on the effects of gastrointestinal flora.
Inclusion Criteria:

 1. Voluntarily signing the informed consent form;

 2. Aged 18-65 years old(including 65), male or female;

 3. Patients aged 35-65 years old(including 35) with positive Helicobacter pylori should
 undergo gastroscopy, and the gastroscopy report shows normal or chronic gastritis;

 4. Patients aged 18-35 years (including 18) with positive Helicobacter pylori are not
 required to perform gastroscopy examination if there is no obvious clinical symptoms,
 or applying report of gastroscopy within 6 months showing normal or chronic gastritis.

 Exclusion Criteria:

 1. Gastroscopy report or previous medical history showed significant esophagus-gastric
 diseases, including gastric cancer, peptic ulcer, oesophagitis and esophageal erosion;

 2. Patients with chronic diarrhea and chronic functional constipation;

 3. Other systemic diseases, including cardiovascular diseases, lung diseases, liver
 diseases (transaminase index is more than 2 times higher than the normal value),
 kidney diseases (creatinine index is higher than the normal value) and other important
 organs with severe lesions, severe metabolic diseases (diabetes, thyroid diseases),
 malignant tumors, and severe immune system diseases;

 4. Abnormal stool routine results: fecal occult blood (+) or white blood cells (+);

 5. Patients with severe psychological or mental diseases;

 6. Those with a history of drug abuse or alcohol abuse;

 7. Those who are allergic to the drugs in this study;

 8. Those who have received Helicobacter pylori eradication therapy;

 9. Drugs which affect the intestinal flora(including antibacterial drugs, microecological
 preparations, intestinal mucosal protectors, Chinese patent medicines, etc.) have been
 used in the past 1 month or need to be used continuously for more than 1 week in the
 experiment.

 10. Pregnant or lactating women;

 11. Participating or after completing other clinical trials Less than 3 months;

 12. Others who researchers consider unsuitable for inclusion.